title: AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF TESTOSTERONE AND CARDIOVASCULAR RISK.
abstract: This document represents the official position of the American Association of Clinical Endocrinologists and the American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.
authors.forename: Neil
authors.initials: N
authors.lastname: Goodman
authors.forename: Andre
authors.initials: A
authors.lastname: Guay
authors.forename: Paresh
authors.initials: P
authors.lastname: Dandona
authors.forename: Sandeep
authors.initials: S
authors.lastname: Dhindsa
authors.forename: Charles
authors.initials: C
authors.lastname: Faiman
authors.forename: Glenn R
authors.initials: GR
authors.lastname: Cunningham
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000209:etiology / Q000517:prevention & control; D032921:Consensus; D004348:Drug Labeling; D004704:Endocrinology; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D007006:Hypogonadism / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D012955:Societies, Medical; D013739:Testosterone / Q000009:adverse effects* / Q000172:deficiency / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D013739:Testosterone